IMPORTANCE Although intermittent androgen-deprivation therapy (ADT) has not been associated with better overall survival in prostate cancer (PC), it has the potential for lower adverse effects. To our knowledge, the incidence of long-term adverse health events has not been reported.
T he methodology to compare experimental with standard therapies through large, randomized clinical trials in a network of large cooperative oncology groups has been refined and improved over decades. The result has been notable improvements in patient survival, and a dramatic increase in the number of cancer survivors in the United States, especially survivors of breast and prostate cancer (PC). 1 Such trials routinely capture detailed patient information on prognostic factors for eligibility, detailed treatment information, short-term acute toxic effects and adverse effect information, cancer recurrence dates, and dates of death. However, the ascertainment of long-term adverse health events following treatment is often a challenge. Ascertainment of adverse health events require the evaluation of large numbers of patients for many years following primary treatment and is typically prohibitively expensive. In addition, some events may not be anticipated or recognized and therefore not attributed to the intervention.
Androgen deprivation therapy (ADT) with gonadotropinreleasing hormone (GnRH) agonists or bilateral orchiectomy, is the mainstay of treatment of metastatic PC, and its use has been increasing steadily over time. 2 Although ADT improves outcomes in patients with PC, it is associated with an array of adverse effects, including sexual dysfunction, bone demineralization, cardiovascular disease, metabolic complications, cognitive changes, and diminished quality of life. 3 To study these outcomes, investigators have used large administrative databases, such as the Surveillance, Epidemiology, and End-Results (SEER)-Medicare database, that contain clinical, demographic, and medical claims data. With regard to skeletal complications, the incidence of vertebral fractures increases by 40% in men on ADT, with longer duration associated with increased risk. 4 Incident diabetes mellitus (DM) is likely an adverse effect of ADT, with 2 reports showing risks of newonset DM ranging from 36% to 49%. 5, 6 Increased cardiovascular mortality has also been reported. In a recent study, GnRH agonist use was associated with increased risk of coronary heart disease (adjusted hazard ratio [HR], 1.16; P < .001), myocardial infarction (adjusted HR, 1.11; P = .03), and sudden cardiac death (adjusted HR, 1.16; P = .004). 5 In addition, an increased risk of acute kidney injury has recently been reported with ADT. 7, 8 These observational studies are often limited owing to selection bias and lack of detailed information on treatments and prognostic factors.
Efforts to minimize toxic effects have focused on the use of intermittent ADT in which the GnRH agonist is started and stopped cyclically to allow androgen levels to return to normal, reducing the hypogonadal period, and potentially reducing adverse effects. In general, patients can experience improvements in quality of life, sexual function, anemia, weight gain, hot flashes, and psychological well-being while not taking ADT; symptoms generally return when ADT is restarted. 9 In 2013, results of 2 randomized clinical trials intensified the controversy with regard to these 2 therapies. In patients with metastatic PC, SWOG 9346 randomized 1535 individuals to continuous or intermittent ADT; while there was a short-term benefit for intermittent therapy in terms of impotence and mental health, intermittent ADT was inferior in terms of survival. 10 In nonmetastatic cancer, a randomized clinical trial found the 2 treatments to be equivalent for cancer control but that intermittent ADT had improved endocrine symptoms. Longterm outcomes were not reported. 11 To overcome some of the challenges of selection and treatment indication bias from observational studies, we have linked the clinical records for patients with PC in SWOG trials to their Medicare administrative claims. Given that older patients are more likely to experience long-term complications from ADT, we examined long-term late adverse events in elderly patients randomized to intermittent or continuous ADT. Our hypothesis was that late cardiovascular and endocrine events would be lower in patients receiving intermittent ADT.
Methods

Clinical Trial Details
We studied patients from SWOG study S9346, a randomized clinical trial of intermittent vs continuous ADT; the study design was previously described. 10 In brief, men with newly diagnosed, metastatic, hormone-sensitive PC were initially registered if they had a performance status of 0 to 2 and a prostate-specific antigen (PSA) level of at least 5 ng/mL. After 7 months of induction GnRH and an antiandrogen, patients whose PSA level fell to 4 ng/mL or less were randomized to continuous vs intermittent ADT. Patients randomized to the intermittent group discontinued ADT and then resumed once the PSA level increased, and discontinued again if, after 7 months, the PSA level fell again to 4 ng/mL or less. Patients were excluded if they had active medical illness that precluded protocol treatment.
Prospective clinical trial data were obtained according to protocol specifications and included demographic factors (age [<65 years vs ≥65 years]), race (black vs white vs other), and data on prognostic factors used in stratification performance status (based on a Zubrod score of 0-1 vs 2), extent of disease (minimal vs extensive), and type of prior hormone therapy (neoadjuvant vs finasteride vs neither). 10 Patients on the trial were followed for 10 years after initial registration or until death, whichever came first.
At a Glance
• Given that older patients are more likely to experience long-term complications from androgen-deprivation therapy (ADT), we examined long-term late events in elderly patients randomized to intermittent or continuous ADT. • We studied patients enrolled in SWOG study S9346, a randomized clinical trial of intermittent vs continuous ADT, who had Medicare claims linked to clinical trial data. • Complications from ADT are common in men in both the intermittent and continuous ADT treatment arms. • Despite a belief that intermittent androgen deprivation would reduce complications from ADT, we found no difference between arms for the endocrine, psychiatric, sexual, or neurologic adverse events. • The 10-year cumulative incidence of ischemic and thrombotic events differed by arm; 24 events for continuous ADT and 33 for intermittent ADT (hazard ratio, 0.69; P = .02).
Study Methods
To identify long-term adverse health events following treatment, we established a linkage between the SWOG clinical records and Medicare claims data. 
Adverse Health Events
Patients were classified as having an adverse health event if they had any hospital claim (Current Procedural Terminology codes)-or at least 2 physician or outpatient claims at least 30 days apart-for any of the following diagnoses: ischemic and thrombotic events (acute myocardial infarction, ischemic heart disease, thrombosis); endocrine events (DM, DM with sequelae, hypercholesterolemia, obesity, osteoporosis, fractures, any bone event); sexual dysfunction, dementia, and depression; and acute kidney injury (eTable 1 in the Supplement). 7, 12, 13 Superficial thrombosis was removed owing to a small number of events. A history of a specific event was defined as any claim within 12 months before study registration. For the analysis of a given adverse event, patients with evidence that the event occurred within 1 year prior to study randomization (ie, preexisting comorbid conditions) were excluded. 14 This was done to emphasize the incidence of new events.
Statistical Analysis
To incorporate time from beginning of observation until evidence of an event, and to account for potential competing risks of death, we analyzed the cumulative incidence from randomization. Data were left truncated given that there may have been a gap between randomization and the initiation of Medicare claims coverage, especially for patients younger than 65 years at randomization. For each event, multivariable competing risk regression analysis was conducted, based on Cox regression (procedure proc phreg; SAS statistical software, version 9.4), to examine time-to-event adjusting for covariates and incorporating left-truncated and right-censored data. 15, 16 The subdistribution HRs, 95% CIs, and P values were generated for each event. In each model, the adverse health event was considered the event of interest and deaths were analyzed as a competing risk; otherwise, patients were censored at their date of last contact if no death was observed. Model covariates included demographic and stratification factors as previously specified. To examine event rates alone by arm (rather than time to event), multivariable logistic regression models were used, adjusting for the same demographic and stratifications as covariates.
Results
A total of 1134 eligible patients from the United States were randomized to continuous or intermittent ADT on S9346. We linked 748 of these patients to Medicare claims, of which 636 (56% of total US-based patients) had at least 1 year of continuous Medicare parts A and B coverage and no HMO participation. This cohort comprised the evaluable patient set for this analysis.
Patient Characteristics
Patient characteristics by intervention assignment are shown in Table 1 . No notable imbalances by arm were observed by age, ethnicity, weight, performance status, extent of disease, or prior hormonal therapy. Most patients had a body mass index, calculated as weight in kilograms divided by height in meters squared, higher than 25 (76%), took no prior hormonal therapy (86%), and had a performance status of 0 to 1 (98%). Patients in this subset had a similar profile to the parent study population. At baseline, there was a small difference in the proportion of patients with DM with sequelae (4% on the continuous arm vs 1% on the intermittent arm; P = .02). Baseline event rates were otherwise similar between the treatment groups for all other events examined. We examined whether survival patterns in the subset of patients with Medicare claims could have influenced ascertainment of adverse health events by arm. The HR of death for intermittent to continuous therapy was 1.14 (95% CI, 0.94-1.38; P = .18) in those with Medicare claims and 1.09 (95% CI, 0.93-1.27; P = .31) in those without Medicare claims. There was no evidence that these survival patterns by arm differed by Medicare claims group (interaction P = .79).
Adverse Events Following ADT
The adverse health events following ADT observed through Medicare claims are shown in Table 2 . Overall, the most common events were endocrine (41% of events), especially hypercholesterolemia (31%). Bone-related events were also common with 19% of men diagnosed as having osteoporosis and 14% having a fracture. Ischemic and thrombotic events were also common (27% of events) with 10% having a claim for ischemic heart disease.
The 10-year cumulative incidence of any ischemic or thrombotic event was 24% for continuous ADT and 33% for intermittent ADT (HR, 0.69; P = .02). The 10-year cumulative incidence of ischemic heart disease alone was 7% for continuous ADT and 12% for intermittent ADT (HR, 0.55; P = .05). There were no statistically significant differences by arm in the cumulative incidence of any other events ( Table 2) . Dementia was observed in 8% of patients receiving continuous ADT and 4% of those receiving intermittent ADT (HR, 1.98; P = .07), however these results should be inter-preted with caution given the low number of reported events. Plots of the predicted cumulative incidence functions for the common adverse health events are shown in the Figure.
Sensitivity Analyses
To rule out the impact of postprogression interventions on patterns of adverse health events, we examined the average impact of randomized treatment on the cumulative incidence of adverse events prior to progression. The median time to progression among patients who progressed was 2.2 years. To avoid selection bias, we truncated follow-up at this time point for all patients. The results were consistent with Copyright 2016 American Medical Association. All rights reserved.
those of the primary results ( Table 3 ), suggesting that observed differences by arm were consistent throughout follow-up. One concern about the primary analysis by randomized assignment is that patients in the intermittent ADT arm may not have received any additional therapy. As a sensitivity analysis, we excluded the 12% of intermittent ADT arm patients with no evidence of receipt of any antiandrogen deprivation consolidation therapy. No substantive differences compared with the primary analysis results were evident (see eTable 2 in the Supplement); however, the increased incidence of dementia in the continuous ADT arm was now significant (HR, 2.51; P = .03). To assess whether potential differences by arm in the duration of ADT influenced the results, we included a timedependent covariate in the multivariable Cox regression models indicating whether the event occurred within 6 months of the completion of ADT. The regression model results by arm were similar (data not shown). Also, in the intermittent ADT arm, there was no difference in the mean percentage of time receiving therapy between those with and without ischemic or thrombotic events (47% vs 47%; P = .86). Finally, for severe thrombosis, fracture, and acute kidney injury, there was no substantial differences in the results when only procedure codes, rather than the combination of diagnosis and procedure codes, were used to identify events (data not shown).
Discussion
Using a novel linkage between elderly patients enrolled in SWOG S9346 and Medicare claims, we have shown that known complications from ADT were common in men on both treatment arms. Despite a belief that intermittent androgen deprivation would reduce complications from ADT, we found no difference between arms for the endocrine, psychiatric, sexual, or neurologic adverse events. In addition, we found an increased cumulative incidence of ischemic and thrombotic events in patients receiving intermittent ADT.
Prior, population-based observational studies have shown an increased risk of cardiovascular disease among men with PC treated with ADT. In a study 17 of patients treated in the Veterans Healthcare Administration, ADT was associated with an increased risk of coronary heart disease (adjusted HR, 1.19), myocardial infarction (adjusted HR, 1.28), and sudden cardiac death (adjusted HR, 1.35). Similar results have been seen with SEER-Medicare. 5 We found a higher cumulative incidence of these events among men receiving intermittent ADT compared with those receiving continuous ADT. This result was unexpected. In 2 prior trials 18, 19 comparing intermittent ADT with continuous ADT, patients in the continuous ADT arm had a higher risk of cardiovascular mortality. Of interest, The P values associated with each curve represent the multivariate competing risk regression P values for the association of treatment and each individual adverse event, adjusting for demographic and stratification. At-risk counts are not always monotonically decreasing owing to left truncation.
reasons for an increase in ischemic events in elderly patients treated with intermittent ADT are unclear, but changes in the coagulation cascade have been reported with lowering of testosterone during ADT as well as with increasing estrogen (after stopping ADT). 21 The risk of vascular events is highest initially, before coagulation cascade homeostasis is reached. 21, 22 In addition, a large study 23 from the Swedish national health registry reported that the risk of incident cardiovascular disease was highest in the first 6 months after initiation of ADT in men with PC, particularly in those with a history of cardiovascular disease. While patients in our study had a high rate of baseline DM and hypercholesterolemia, there was no difference in claims between the treatment groups. Compared with patients not receiving ADT, the incidence of vertebral fractures increases by 40% in men prescribed ADT, with longer duration associated with increased risk. 4 In our study, bone events (osteoporosis or fracture) were common in both the intermittent and continuous ADT arms but were not different between arms. The cumulative incidence of these events was slightly higher than in a previous report 24 with shorter follow-up. The rates of skeletal events may be an underestimate of actual rates because all patients were randomized after receiving 7 months of ADT. It is also possible that events were misclassified as PC progression. A prior study 25 has shown that the largest decline in bone mineral density occurs during the first ADT on-treatment period with substantial heterogeneity in subsequent cycles. It is also possible that there were inaccuracies in the submission of the claims. Finally, it was not known which patients were receiving bisphosphonate therapy, which may have affected the fracture rate.
It is assumed that the main advantage of intermittent ADT seems to be a reduction in short-term symptoms while a patient is receiving ADT and reduced ADT cost. In a recent systematic review 26 of trials comparing intermittent with continuous ADT, 6 of the 9 trials evaluated quality of life and treatment-related adverse effects. In some of the trials, patients prescribed intermittent ADT had improved sexual function, physical activity, and general well-being, but these results often did not persist over time, and there was significant superiority of overall quality of life only for men receiving intermittent ADT in 1 study. In the results from the primary study 10 there were no differences in grade 3 or 4 treatmentrelated adverse events between the intermittent (30.4%) and continuous (32.7%) ADT groups, and no difference in cardiovascular events. It is possible that differences in severity may have resulted in the submission of claims for events that were not captured by event reporting; however, we would expect that bias to be similar by arm given the random assignment of treatments. It is also possible that not all toxic effects are captured in clinical trials, especially if the event was unknown to the primary investigative team. This difference may increase as a patient is further out from randomization and study monitoring becomes less frequent.
We acknowledge several limitations of our study and of the Medicare database in general. Although we required participants to have 2 claims to reduce misclassification bias, a process routinely performed in studies using administrative claims, it is still possible that not all patients with Medicare claims had the complication we assigned. [27] [28] [29] It is also possible that the patients who experienced toxic effects did not have claims associated with it. Medicare lacks data on the severity of the toxic effects; therefore, it is possible that these complications were mild and not life-threatening and therefore not known to research staff reporting adverse events. Alternatively, because mild complications are sometimes not captured with billing data, our findings may have underestimated some complications in these older men. However, we would anticipate that this misclassification bias would not differ between randomly assigned treatments. We did not adjust for multiple comparisons; thus, more marginal results may be more likely due to chance. Any positive findings should be confirmed in other studies. It is also possible that our results are not generalizable to younger patients in whom complication rates may be lower; however, PC is more common in elderly men. Finally, all of the patients were enrolled in a randomized clinical trial, and therefore these results may not be generalizable to all patients who did not meet eligibility criteria for S9346. Most patients had a performance status of 0 or 1. This study has several unique strengths. Unlike previous observational studies of late toxic effects, our study benefited from random assignment between the arms, reducing the potential for unmeasured confounders to influence the treatment decisions as well as the outcomes. In addition, the extent of disease and prior therapy were known for all participants. Also, evaluation of intermittent ADT with observational data would be complex because PSA results and the reason for the treatment gap would not be captured in billing claims. Finally, we used methodology in defining outcome events similar to those of many prior investigators using claims data.
Conclusions
We did not find that patients randomly assigned to intermittent ADT had consistently fewer long-term adverse health events compared with those assigned to continuous ADT. In fact, unexpectedly, we observed that elderly men assigned to intermittent ADT had an increased incidence of ischemic and thrombotic events. If these finding are confirmed, given the failure of the parent study to prove its noninferiority end point, clinicians should be cautious about using intermittent ADT therapy in older men with metastatic PC given our inability to demonstrate a reduction in long-term adverse health events, the primary rationale for intermittent ADT. Discussion about the relative merits of intermittent vs continuous androgen-deprivation therapy (ADT) for treatment of prostate cancer has for many years occupied prostate cancer researchers and patients. The concept of intermittent ADT is based on evidence from animal models that development of the castration-resistant state may be delayed as compared with continuous ADT 1 and that reduced exposure to ADT is likely to be associated with less likelihood of harms from treatment. Several randomized clinical trials (RCTs) and 4 metaanalyses have since compared intermittent with continuous ADT in men with various stages of prostate cancer and have failed to demonstrate better survival with one strategy vs the other. Data on adverse events (AEs) and quality of life (QOL) are even less consistent and inadequately reported by most trials.
In this issue of JAMA Oncology, a thought-provoking article by Hershman et al 2 has enriched the literature with information about risks of cumulative toxic effects in men treated with intermittent vs continuous ADT. The authors 2 linked American men with prostate cancer who were enrolled in the SWOG S9346 clinical trial 3 with their respective Medicare claims to investigate differences in 10-year cumulative incidence of long-term AEs defined by hospital claims or by 2 or more outpatient claims at least 30 days apart. The authors 2 grouped AEs under 5 headings: ischemia and thrombosis, endocrine events, sexual dysfunction, dementia and depression, and acute kidney injury. There were high rates of occurrence of these AEs overall, although the authors 2 did not find significant differences between the arms for 4 of them. However, they report a 31% lower risk of ischemia and thrombosis with the use of continuous compared with intermittent ADT, which was statistically significant. As the authors 2 acknowledge, this finding is counterintuitive and its interpretation demands consideration.
The SWOG S9346 trial was designed to assess whether intermittent ADT was noninferior to continuous ADT with respect to overall survival, with a co-primary end point of QOL at 3 months after randomization. 3 The trial failed to demonstrate noninferiority of overall survival of intermittent ADT compared with continuous ADT, but it did not prove superiority of continuous ADT, as stated incorrectly in the article by Hershman et al. 2 There was evidence of superior QOL in the intermittent arm at 3 months in terms of erectile function, overall mental health, and libido, but that diminished after 15 months on study, perhaps because most men eventually received continuous ADT. 3 The main caveat of the current report 2 lies in its methodological limitations. Neither the primary SWOG study nor the current one 2 was powered adequately to examine differences in occurrence of toxic effects between the 2 strategies. The current study is an exploratory analysis of 636 patients from an administrative database selected from the randomized groups (not itself an RCT, although the eligible patients appeared well balanced for important factors), and it did not correct for multiple significance testing. Therefore, despite the reported statistical significance (P = .02), the study does not prove statistical superiority of continuous ADT in terms of thromboembolic and ischemic events, although given the direction of the trend, it is highly unlikely that a larger RCT would find them to be reduced with intermittent ADT. Also, AEs may not be well captured in administrative databases, as evidenced by the very low rate of overall sexual dysfunction (6%) reported in Table 2 of the study, 2 although thromboembolic events are much more likely to lead to medical visits than sexual dysfunction.
Inability to reproduce research findings has been identified as a major challenge in modern scientific research-a limitation that is not confined to retrospective and epidemiological studies but extends to large, phase 3 RCTs. Positive results based on P values are refuted frequently in subsequent studies. 4 Reproducibility of results is more important than level of significance claimed in a single study, and it is important that these findings be validated in other trials comparing intermittent and continuous ADT.
It is well established from multiple studies that prostate cancer itself, regardless of use of ADT, is associated with a high
